Joaquim Bellmunt, MD, PhD

Articles

Improving Workflow and ctDNA Adoption in MIBC Care

December 15th 2025

Experts discuss the operational challenges and evolving use of Cignaera in cancer treatment, highlighting its potential benefits in patient care.

Challenges in Standardizing ctDNA-guided MRD Testing in MIBC

December 15th 2025

Explore the challenges and advancements in ctDNA-based testing for cancer care, focusing on personalized approaches and sensitivity in diverse tumor types.

Improving Patient Communication and Treatment Decisions with ctDNA Monitoring in MIBC

December 8th 2025

Experts discuss the significance of ctDNA testing in cancer treatment, highlighting its role in patient prognosis and treatment decisions.

Integrating ctDNA-Based MRD Testing in MIBC

December 8th 2025

The Signara assay enhances mutation tracking in urothelial cancer, improving patient outcomes through informed treatment decisions and timely interventions.

Dr Bellmunt on Future Directions With ctDNA-Guided Immunotherapy in Urothelial Cancer

December 3rd 2025

Joaquim Bellmunt, MD, PhD, discusses future research directions with ctDNA-guided immunotherapy in urothelial cancer.

Unmet Needs and the Evolving Role of MRD Monitoring in MIBC

December 1st 2025

Discover the latest insights on ctDNA testing and its impact on relapse risk in muscle-invasive bladder cancer post-surgery.

Risk Stratification and Surveillance After

December 1st 2025

Experts discuss the evolving treatment landscape for muscle-invasive bladder cancer, highlighting the shift towards perioperative approaches and the role of biomarkers.

Dr Bellmunt on Adjuvant Atezolizumab in Patients With MIBC Who Were ctDNA+ After Initial Testing

November 28th 2025

Joaquim Bellmunt, MD, PhD, discusses subgroup and safety data from the phase 3 IMvigor011 trial in patients with MIBC.

Analyzing the Role of ctDNA and Adjuvant

November 20th 2025

Experts discuss the evolving role of ctDNA in adjuvant therapy post-cystectomy, highlighting its prognostic value and implications for treatment decisions.

Biomarker, Diagnosis, and Evolving Treatment Paradigm in MIBC

November 20th 2025

Recent discussions highlight the significance of ctDNA in adjuvant therapy post-cystectomy, revealing its potential to predict patient outcomes and guide treatment decisions.

Dr Bellmunt on Efficacy Findings With ctDNA-Guided Adjuvant Atezolizumab in MIBC

November 19th 2025

Joaquim Bellmunt, MD, PhD, discusses the efficacy data seen with ctDNA-guided adjuvant atezolizumab in MIBC.

Advancements in Perioperative Therapy for MIBC

November 13th 2025

Experts discuss the promising results of the Niagara trial, highlighting benefits of cisplatin and durvalumab for unfit patients in cancer treatment.

Novel Neoadjuvant Therapies in MIBC

November 13th 2025

Experts discuss advancements in muscle invasive bladder cancer, focusing on innovative testing and treatment strategies to enhance patient outcomes.

Dr Bellmunt on the Design of the IMvigor011 Trial of ctDNA-Guided Adjuvant Atezolizumab in MIBC

November 12th 2025

Joaquim Bellmunt, MD, PhD, discusses the phase 3 IMvigor011 trial of ctDNA-guided adjuvant atezolizumab in MIBC.

Dr Bellmunt on Avelumab Maintenance in Advanced Urothelial Carcinoma With Low Tumor Burden

June 18th 2024

Joaquim Bellmunt, MD, PhD discusses findings from a post-hoc analysis for avelumab maintenance in advanced urothelial carcinoma with low tumor burden.

Dr Bellmunt on Predictive Signatures for Checkpoint Inhibitor Responses in Urothelial Cancer

June 11th 2024

Joaquim Bellmunt, MD, PhD, discusses the predictive value of H3K27ac epigenomic and single-cell transcriptional profiling in urothelial cancer.

Dr Bellmunt on Enfortumab Vedotin/Pembrolizumab in the Community Setting for Urothelial Carcinoma

May 13th 2024

Joaquim Bellmunt, MD, PhD, discusses treatment with enfortumab vedotin plus pembrolizumab in patients with urothelial carcinoma in the community setting.

Dr Bellmunt on the Impact of Treatment With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

May 2nd 2024

Joaquim Bellmunt, MD, PhD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab impacts the urothelial cancer treatment paradigm.

Dr. Bellmunt Highlights Immunotherapy Options in Bladder Cancer

January 4th 2019

Joaquim Bellmunt, MD, PhD, genitourinary oncologist, Beth Israel Deaconess Medical Center, associate professor of medicine, Harvard Medical School, differentiates between immunotherapy options available for the treatment of patients with in bladder cancer.

Dr. Bellmunt on The Cancer Genome Atlas Project in Bladder Cancer

April 5th 2018

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses The Cancer Genome Atlas (TCGA) project in bladder cancer.